OGI vs. LYEL, NUVB, SAGE, OLMA, MLYS, ABUS, AVBP, DNTH, PHAR, and ANAB
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Lyell Immunopharma (LYEL), Nuvation Bio (NUVB), Sage Therapeutics (SAGE), Olema Pharmaceuticals (OLMA), Mineralys Therapeutics (MLYS), Arbutus Biopharma (ABUS), ArriVent BioPharma (AVBP), Dianthus Therapeutics (DNTH), Pharming Group (PHAR), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical preparations" industry.
Lyell Immunopharma (NASDAQ:LYEL) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Organigram received 184 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 70.61% of users gave Organigram an outperform vote while only 56.52% of users gave Lyell Immunopharma an outperform vote.
Organigram has a net margin of -188.38% compared to Organigram's net margin of -335,794.09%. Organigram's return on equity of -33.92% beat Lyell Immunopharma's return on equity.
Lyell Immunopharma has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
Lyell Immunopharma presently has a consensus target price of $5.50, suggesting a potential upside of 126.34%. Given Organigram's higher possible upside, equities research analysts clearly believe Lyell Immunopharma is more favorable than Organigram.
In the previous week, Lyell Immunopharma had 2 more articles in the media than Organigram. MarketBeat recorded 2 mentions for Lyell Immunopharma and 0 mentions for Organigram. Organigram's average media sentiment score of 0.00 equaled Lyell Immunopharma'saverage media sentiment score.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 34.6% of Organigram shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by insiders. Comparatively, 0.1% of Organigram shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Organigram has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Summary
Lyell Immunopharma and Organigram tied by winning 8 of the 16 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
